Glucocorticoid sensitivity in humans

Current Opinion in Endocrinology and Diabetes

Volumn 5, Issue 3, 1998, Pages 168-174

  Walker, Brian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE;

DRUG MECHANISM; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEGATIVE FEEDBACK; REVIEW; SIGNAL TRANSDUCTION; STEROID METABOLISM;

EID: 0031807485     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199806000-00004     Document Type: Review

References (78)

1. Reynolds PD, Pittler SJ, Scammell JG: Cloning and expression of the glucocorticoid receptor from the squirrel monkey (Saimiri boliviensis boliviensis), a glucocorticold-resistant primate. J Clin Endocrinol Metab 1997, 82:465-472.
2. Klein SL, Taymans SE, DeVries AC, Nelson RJ: Cellular immunity is not compromised by high serum corticosterone concentrations in prairie voles. Am J Physiol 1996, 271:R1608-R1613.
3. Taymans SE, DeVries AC, DeVries MB, Nelson RJ, Friedman TC, Castro M, Detera-Wadleigh S, Carter CS, Chrousos GP: The hypothalamic-pituitary-adrenal axis of prairie voles (Microtus ochrogaster): evidence for target tissue glucocorticoid resistance. Gen Comp Endocrinol 1997, 106:48-61.
4. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CRW: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosterold reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995, 80:3155-3159.
5. Rajan V, Edwards CRW, Seckl JR: 11β-Hydroxysteroid dehydrogenase in cultured hippocampal cells reactivates inert 11-dehydrocorticosterone, potentiating neurotoxicity. J Neurosci 1996, 16:65-70.
6. Jamieson PM, Chapman KE, Edwards CRW, Seckl JR: 11β-Hydroxysteroid dehydrogenase is an exclusive 11β-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995, 136:4754-4761.
7. Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect 'Cushing's disease of the omentum?' Lancet 1997, 349:1210-1213.
8. Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996, 17:245-261.
9. Hirano T, Horigome A, Oka K, Takeuchi H, Yoshida M, Sakurai E, Kozaki K, Matsuno N, Nagao T, Kozaki M: Glucocorticoid-resistance in peripheral-blood lymphocytes does not correlate with number or affinity of glucocorticoid-receptors in chronic renal failure patients. Immunopharmacology 1997, 36:57-67.
10. DeRijk RH, Petrides J, Deuster P, Gold PW, Sternberg EM: Changes in corticosteroid sensitivity of peripheral blood lymphocytes after strenuous exercise in humans. J Clin Endocrinol Metab 1996, 81:228-235.
11. Panarelli M, Holloway CD, Mulatero P, Fraser R, Kenyon CJ: Inhibition of lysozyme synthesis by dexamethasone in human mononuclear leukocytes: an Index of glucocorticoid sensitivity. J Clin Endocrinol Metab 1994, 78:872-877.
12. Wei T, Knight RA, Lightman SL: Mitogenic response and steroid sensitivity in MS lymphocytes. Acta Neurol Scand 1997, 96:28-33.
13. Briggs WA, Gao Z-H, Xing J-J, Scheel PJJ, Burdick JF: Differential glucocorticoid responsiveness of hemodialysls patients' lymphocytes. ASAIO J 1997, 43:31-34.
14. Nijhuis EP, Oostervink F, Hinloopen B, Rozing J, Nagelkerken L: Differences in dexamethasone-sensitivity between lymphocytes from patients with Alzhelmer's disease and patients with multi-infarct dementia. Brain Behav Immun 1996, 10:115-125.
15. Csoka M, Bocsi J, Falus A, Szalai C, Klujber V, Szende B, Schuler D: Glucocorticoid-induced apoptosis and treatment sensitivity in acute lymphoblastic leukemia of children. Pediatr Hematol Oncol 1997, 14:433-442.
16. Koper JW, Stolk RP, De Lange P, Huizenga NM, Molijn G-J, Pols HP, Grobbee DE, Karl M, de Jong FH, Brinkmann AO, Lamberts SJ: Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet 1997, 99:663-668.
17. Best R, Nelson SM, Walker BR: Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11β-hydroxysteroid dehydrogenase in vitro and in vivo. J Endocrinol 1997, 153:41-48.
18. Meacham LR, Abdul-Latif H, Sullivan K, Culler FL: Predictors of change in insulin sensitivity during glucocorticoid treatment. Horm Metab Res 1997, 29:172-175.
19. Wajngot A, Giacca A, Grill V, Vranic M, Efendic S: The diabetogenic effects of glucocorticoids are more pronounced in low-than in high-insulin responders. Proc Natl Acad Sci U S A 1992, 89:6035-6039.
20. McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962, 86:608-610.
21. Burdick KH: Various vagaries of vasoconstriction. Arch Dermatol 1974, 110:238-242.
22. Noon JP, Evans CE, Haynes WG, Webb DJ, Walker BR: A comparison of techniques to assess skin blanching following topical application of glucocorticoids. Br J Dermatol 1996, 134:837-842.
23. Palermo M, Shackleton CHL, Mantero F, Stewart PM: Urinary free cortisone and the assessment of 11beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996, 45:605-611. This paper, along with that of Best and Walker (Clin Endocrinol [Oxf] 1997, 47:231-236), illustrates that measurement of urinary free cortisol-to-cortisone concentrations may measure renal 11β-hydroxysteroid dehydrogenase type 2 activity independently of the influence of 11β-hydroxysteroid dehydrogenase type 1 activity in other tissues, both in congenital deficiency syndromes (the present article) and after pharmacologic inhibition (Best and Walker). Given the importance of cortisol metabolism in dictating tissue sensitivity to cortisol, a key step will be to improve our ability to distinguish tissue-specific enzyme activities in more detail.
24. Palermo M, Shackleton CHL, Mantero F, Stewart PM: Urinary free cortisone and the assessment of 11beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996, 45:605-611. This paper, along with that of Best and Walker (Clin Endocrinol [Oxf] 1997, 47:231-236), illustrates that measurement of urinary free cortisol-to-cortisone concentrations may measure renal 11β-hydroxysteroid dehydrogenase type 2 activity independently of the influence of 11β-hydroxysteroid dehydrogenase type 1 activity in other tissues, both in congenital deficiency syndromes (the present article) and after pharmacologic inhibition (Best and Walker). Given the importance of cortisol metabolism in dictating tissue sensitivity to cortisol, a key step will be to improve our ability to distinguish tissue-specific enzyme activities in more detail.
25. Best R, Walker BR: Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol(Oxf) 1997, 47:231-236. This paper, along with that of Palermo et al. (Clin Endocrinol (Oxf) 1996, 45:605-611), illustrates that measurement of urinary free cortisol-to-cortisone concentrations may measure renal 11β-hydroxysteroid dehydrogenase type 2 activity independently of the influence of 11β-hydroxysteroid dehydrogenase type 1 activity in other tissues, both in congenital deficiency syndromes (Palermo et al.) and after pharmacologic inhibition (the present article). Given the importance of cortisol metabolism in dictating tissue sensitivity to cortisol, a key step will be to improve our ability to distinguish tissue-specific enzyme activities in more detail.
26. Best R, Walker BR: Additional value of measurement of urinary cortisone and unconjugated cortisol metabolites in assessing the activity of 11β-hydroxysteroid dehydrogenase in vivo. Clin Endocrinol(Oxf) 1997, 47:231-236. This paper, along with that of Palermo et al. (Clin Endocrinol (Oxf) 1996, 45:605-611), illustrates that measurement of urinary free cortisol-to-cortisone concentrations may measure renal 11β-hydroxysteroid dehydrogenase type 2 activity independently of the influence of 11β-hydroxysteroid dehydrogenase type 1 activity in other tissues, both in congenital deficiency syndromes (Palermo et al.) and after pharmacologic inhibition (the present article). Given the importance of cortisol metabolism in dictating tissue sensitivity to cortisol, a key step will be to improve our ability to distinguish tissue-specific enzyme activities in more detail.
27. Iida S, Nakamura Y, Fujii H, Nishmura J-I, Tsugawa M, Gomi M, Fukata J, Tarui S, Morikawa K, Kitani T: A patient with hypocortisolism and Cushing's syndrome-like manifestations: cortisol hyperreactive syndrome. J Clin Endocrinol Metab 1990, 70:729-737.
28. Lamberts SWJ, Koper JW, de Jong FH: Familial and latrogenic cortisol receptor resistance. J Steroid Biochem Mol Biol 1992, 43:385-388.
29. Bronnegard M, Stierna P, Marcus S: Glucocorticoid resistant syndromes: molecular basis and clinical presentations. J Neuroendocrinol 1996, 8:405-415.
30. Stratakis CA, Karl M, Schulte HM, Chrousos GP: Glucocorticosteroid resistance in humans: elucidation of the molecular mechanisms and implications for pathophysiology. Ann N Y Acad Sci 1994, 746:362-376.
31. Phillipou G, Higgins BA: A new defect in the peripheral conversion of cortisone to cortisol. J Steroid Biochem 1985, 22:435-436.
32. Phillipou G, Palermo M, Shackleton CHL: Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 1996, 81:3855-3860.
33. Koteletsev Y, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, Best R, Brown RW, Edwards CRW, Seckl JR, Mullins JJ: 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. Proc Natl Acad Sci U S A 1997, 94:14924-14929.
34. Nimmagadda SR, Spahn JD, Leung DM, Szefler SJ: Steroid-resistant asthma: evaluation and management Ann Allergy 1996, 77:345-356.
35. Brown PH, Teelucksingh S, Matusiewicz SP, Greening AP, Crompton GK, Edwards CRW: Cutaneous vasoconstrictor response to glucocorticoids in asthma. Lancet 1991, 337:576-580.
36. Carmichael J, Paterson IC, Diaz P, Crompton GK, Kay AB, Grant IWB: Corticosteroid resistance In chronic asthma. Br Med J 1981, 282:1419-1422.
37. Corrigan CJ, Bungre JK, Assoufi B, Cooper AE, Seddon H, Kay AB: Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocortlcoids and immunosuppressive agents. Eur Respir J 1996, 9:2077-2086.
38. Sher ER, Leung DY, Surs W, Kam JC, Zeig G, Kamada AK, Szefler SJ: Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994, 93:33-39.
39. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ: Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995, 182:1951-1958.
40. Guo W-X, Antakly T, Cadotte M, Kachra Z, Kunkel L, Masood R, Gill P: Expression and cytokine regulation of glucocorticoid receptors in Kaposi's sarcoma. Am J Pathol 1996, 148:1999-2008.
41. Karl M, Von Wichert G, Kempter E, Katz DA, Reincke M, Monig H, Ali IU, Stratakis CA, Oldfield EH, Chrousos GP, Schulte HM: Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996, 81:124-129. Raises the important possibility that mutations in the glucocorticoid receptor underlie the pathogenesis of Cushing's syndrome, but this hypothesis has not been supported in other studies (see Dahia et al. [J Clin Endocrinol Metab 1997, 82:1088-1093]).
42. Karl M, Von Wichert G, Kempter E, Katz DA, Reincke M, Monig H, Ali IU, Stratakis CA, Oldfield EH, Chrousos GP, Schulte HM: Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J Clin Endocrinol Metab 1996, 81:124-129. Raises the important possibility that mutations in the glucocorticoid receptor underlie the pathogenesis of Cushing's syndrome, but this hypothesis has not been supported in other studies (see Dahia et al. [J Clin Endocrinol Metab 1997, 82:1088-1093]).
43. Hala M, Hartmann BL, Bock G, Geley S, Kofler R: Glucocorticoid-receptor-gene defects and resistance to glucocorticoid-induced apoptosis in human leukemic cell lines. Int J Cancer 1996, 68:663-668.
44. Kojika S, Sugita K, Inukai T, Saito M, Iijima K, Tezuka T, Goi K, Shiraishi K, Mori T, Okazaki T, Kagami K, Ohyama K, Nakazawa S: Mechanisms of glucocorticoid resistance in human leukemic cells: implication of abnormal 90 and 70 kDa heat shock proteins. Leukemia 1996, 10:994-999.
45. Dahia PM, Honegger J, Reincke M, Jacobs RA, Mirtella A, Fahlbusch R, Besser GM, Chew SL, Grossman AB: Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. J Clin Endocrinol Metab 1997, 82:1088-1093.
46. Rook GAW, Lightman SL (eds.): Steroid Hormones and the T-cell Cytokine Profile. London: Springer; 1997.
47. Costas M, Trapp T, Pereda MP, Sauer J, Rupprecht R, Nahmod VE, Reul JMHM, Holsboer F, Arzt E: Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids: TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis. J Clin Invest 1996, 98:1409-1416.
48. Costa MA, Kovalovsky D, Arzt E: Mechanisms of glucocorticoid sensitivity modulation by cytokines. Medicine 1997, 57:75-60.
49. Miller AH, Spencer RL, Pearce BD, Pisell TL, Tanapat P, Leung JJ, Dhabhar FS, McEwen BS, Biron CA: Effects of viral Infection on corticosterone secretion and glucocorticoid receptor binding in immune tissues. Psychoneuroendocrinology 1997, 22:455-474.
50. Norbiato G, Bevilacqua M, Vago T: Glucocorticoids and the immune system in AIDS. Psychoneuroendocrinology 1997, 22:S19-S25.
51. Norbiato G, Bevilacqua M, Vago T: Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1996, 81:2601-2606.
52. Rook GAW, Honour J, Kon OM, Wilkinson RJ, Davidson R, Shaw RJ: Urinary adrenal steroid metabolites In tuberculosis: a new clue to pathogenesls? Q J Med 1996, 89:333-341.
53. Ljung T, Andersson B, Bengtsson B, Bjomtorp P, Marin P: Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 1996, 4:277-282.
54. Weaver JU, Hitman GA, Kopelman PG: An association between a Bcl restriction fragment length polymorphism of the glucocorticoid receptor locus and hyperinsullnaemla in obese women. J Mol Endocrinol 1992, 9:295-300.
55. Clement K, Philippi A, Jury C, Pividal R, Hager J, Demenais F, Basdevant A, Guy-Grand B, Froguel P: Candidate gene approach of familial morbid obesity: linkage analysis of the glucocorticoid receptor gene. Int J Obes 1996, 20:507-512.
56. Valletta G, Vanet A, Sumida C, Nunez EA: Modulatory effects of unsaturated fatty acids on the binding of glucocorticoids to rat liver glucocorticoid receptors. Endocrinology 1991, 129:1363-1369.
57. Rodin A, Thakkar H, Taylor N, Clayton R: Hyperandrogenism in polycystic ovary syndrome: evidence of dysregulation of 11beta-hydroxysteroid dehydrogenase. N Engl J Med 1994, 330:460-465.
58. Walker BR: Abnormal glucocorticoid activity in subjects with risk factors for cardiovascular disease. Endocr Res 1996, 22:701-708.
59. Walker BR, Best R, Skackleton CHL, Padfield PL, Edwards CRW: Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996, 27:190-196. Both this article and that of Walker et al. (Hypertension 1998, in press) show that subjects who are sensitive to glucocorticoids in the skin (using the skin blanching assay) are predisposed to hypertension, insulin resistance, and glucose intolerance, independently of cortisol secretion and other cardiovascular risk factors. These data provide a novel paradigm to explain the association among multiple cardiovascular risk factors, invoking enhanced tissue sensitivity to cortisol.
60. Walker BR, Best R, Skackleton CHL, Padfield PL, Edwards CRW: Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension 1996, 27:190-196.
61. Walker BR, Phillips DIW, Noon JP, Panarelli M, Best R, Edwards HE, Holton DW, Seckl JR, Webb DJ, Watt GCM: Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998, in press.
62. Walker BR, Phillips DIW, Noon JP, Panarelli M, Best R, Edwards HE, Holton DW, Seckl JR, Webb DJ, Watt GCM: Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998, in press.
63. Walker BR, Stewart PM, Shackleton CHL, Padfield PL, Edwards CRW: Deficient inactivation of cortisol by 11β-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol (Oxf) 1993, 39:221-227.
64. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R: Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in patients with untreated essential hypertension. Hypertension 1995, 25:67-70.
65. Watt GCM, Harrap SB, Foy CJW, Holton DW, Edwards HV, Davidson HR, Connor JM, Lever AF, Fraser R: Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four corners approach to the identification of genetic determinants of blood pressure. J Hypertens 1992, 10:473-482.
66. Law CM, Shiell AW: Is blood pressure Inversely related to birth weight? The strength of evidence from a systematic review of the literature. J Hypertens 1996, 14:935-941.
67. Phillips DIW, Borthwick AC, Stein C, Taylor R: Fetal growth and insulin resistance in adult life: relationship between glycogen synthase activity in adult skeletal muscle and birth weight. Diabet Med 1996, 13:325-329.
68. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW: Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993, 341:339-341.
69. Lindsay RS, Lindsay RM, Waddell BJ, Seckl JR: Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996, 39:1299-1305.
70. Lindsay RS, Lindsay RM, Edwards CRW, Seckl JR: Inhibition of 11β-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Am J Physiol 1996, 27:1200-1204.
71. Levitt NS, Holmes MC, Lindsay RS, Seckl JR: Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology 1996, 64:412-418. This paper and that of Phillips et al. (J Clin Endocrinol Metab 1998, 83:757-760) show that in both rats and humans, low birth weight can be associated with higher circulating glucocorticoid levels in adulthood. In rats, this association may be explained by programming of negative feedback glucocorticoid sensitivity.
72. Levitt NS, Holmes MC, Lindsay RS, Seckl JR: Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology 1996, 64:412-418. This paper and that of Phillips et al. (J Clin Endocrinol Metab 1998, 83:757-760) show that in both rats and humans, low birth weight can be associated with higher circulating glucocorticoid levels in adulthood. In rats, this association may be explained by programming of negative feedback glucocorticoid sensitivity.
73. Phillips DIW, Barker DJP, Fall CHD, Whorwood CB, Seckl JR, Wood PJ, Walker BR: Elevated plasma cortisol concentrations: an explanation for the relationship between low birthweight and adult cardiovascular risk factors. J Clin Endocrinol Metab 1998, 83:757-760. This paper and that of Levitt et al. (Neuroendocrinology 1996, 64:412-418) show that in both rats and humans, low birth weight can be associated with higher circulating glucocorticoid levels in adulthood. In rats, this association may be explained by programming of negative feedback glucocorticoid sensitivity.
74. Phillips DIW, Barker DJP, Fall CHD, Whorwood CB, Seckl JR, Wood PJ, Walker BR: Elevated plasma cortisol concentrations: an explanation for the relationship between low birthweight and adult cardiovascular risk factors. J Clin Endocrinol Metab 1998, 83:757-760. This paper and that of Levitt et al. (Neuroendocrinology 1996, 64:412-418) show that in both rats and humans, low birth weight can be associated with higher circulating glucocorticoid levels in adulthood. In rats, this association may be explained by programming of negative feedback glucocorticoid sensitivity.
75. Wilkinson CW, Peskind ER, Raskind MA: Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology 1997, 65:79-90.
76. Linder J, Nolgard P, Nasman B, Back O, Uddhammar A, Olsson T: Decreased peripheral glucocorticoid sensitivity in Alzheimer's disease. Gerontology 1993, 39:200-206.
77. Seckl JR, Olsson T: Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect? J Endocrinol 1995, 145:201-211.
78. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W: Anti-glucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biol 1994, 131:99-104.